JP2021515005A5 - - Google Patents

Download PDF

Info

Publication number
JP2021515005A5
JP2021515005A5 JP2020545532A JP2020545532A JP2021515005A5 JP 2021515005 A5 JP2021515005 A5 JP 2021515005A5 JP 2020545532 A JP2020545532 A JP 2020545532A JP 2020545532 A JP2020545532 A JP 2020545532A JP 2021515005 A5 JP2021515005 A5 JP 2021515005A5
Authority
JP
Japan
Prior art keywords
oxytocin peptide
labeled
composition
labeled oxytocin
oxytocin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020545532A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019169342A5 (https=
JP2021515005A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/020419 external-priority patent/WO2019169342A1/en
Publication of JP2021515005A publication Critical patent/JP2021515005A/ja
Publication of JPWO2019169342A5 publication Critical patent/JPWO2019169342A5/ja
Publication of JP2021515005A5 publication Critical patent/JP2021515005A5/ja
Priority to JP2024009405A priority Critical patent/JP2024038482A/ja
Priority to JP2025230634A priority patent/JP2026035830A/ja
Priority to JP2025230635A priority patent/JP2026035831A/ja
Pending legal-status Critical Current

Links

JP2020545532A 2018-03-01 2019-03-01 標識オキシトシンならびに製造および使用の方法 Pending JP2021515005A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2024009405A JP2024038482A (ja) 2018-03-01 2024-01-25 標識オキシトシンならびに製造および使用の方法
JP2025230634A JP2026035830A (ja) 2018-03-01 2025-12-04 標識オキシトシンならびに製造および使用の方法
JP2025230635A JP2026035831A (ja) 2018-03-01 2025-12-04 標識オキシトシンならびに製造および使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862637187P 2018-03-01 2018-03-01
US62/637,187 2018-03-01
PCT/US2019/020419 WO2019169342A1 (en) 2018-03-01 2019-03-01 Labeled oxytocin and method of manufacture and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024009405A Division JP2024038482A (ja) 2018-03-01 2024-01-25 標識オキシトシンならびに製造および使用の方法

Publications (3)

Publication Number Publication Date
JP2021515005A JP2021515005A (ja) 2021-06-17
JPWO2019169342A5 JPWO2019169342A5 (https=) 2022-03-07
JP2021515005A5 true JP2021515005A5 (https=) 2022-03-07

Family

ID=65763911

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020545532A Pending JP2021515005A (ja) 2018-03-01 2019-03-01 標識オキシトシンならびに製造および使用の方法
JP2024009405A Withdrawn JP2024038482A (ja) 2018-03-01 2024-01-25 標識オキシトシンならびに製造および使用の方法
JP2025230635A Pending JP2026035831A (ja) 2018-03-01 2025-12-04 標識オキシトシンならびに製造および使用の方法
JP2025230634A Pending JP2026035830A (ja) 2018-03-01 2025-12-04 標識オキシトシンならびに製造および使用の方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2024009405A Withdrawn JP2024038482A (ja) 2018-03-01 2024-01-25 標識オキシトシンならびに製造および使用の方法
JP2025230635A Pending JP2026035831A (ja) 2018-03-01 2025-12-04 標識オキシトシンならびに製造および使用の方法
JP2025230634A Pending JP2026035830A (ja) 2018-03-01 2025-12-04 標識オキシトシンならびに製造および使用の方法

Country Status (4)

Country Link
US (2) US11970554B2 (https=)
EP (1) EP3759121A1 (https=)
JP (4) JP2021515005A (https=)
WO (1) WO2019169342A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3759121A1 (en) * 2018-03-01 2021-01-06 Trigemina, Inc. Labeled oxytocin and method of manufacture and use
US11631208B1 (en) * 2021-12-22 2023-04-18 RealizeMD Ltd. Systems and methods for generating clinically relevant images that preserve physical attributes of humans while protecting personal identity
US11935238B2 (en) * 2021-12-22 2024-03-19 RealizeMD Ltd. Systems and methods for generating clinically relevant images that preserve physical attributes of humans while protecting personal identity
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1936364A (en) 1930-08-22 1933-11-21 Pfizer Charles & Co Citrate solutions
US2260004A (en) 1939-11-03 1941-10-21 Pfizer Charles & Co Stable soluble magnesium acid citrate
US2938891A (en) 1956-03-30 1960-05-31 Roussel Uclaf Method of making oxytocin and intermediates thereof
US3076797A (en) 1957-07-22 1963-02-05 Roussel Uclaf Process of producing oxytocin and intermediates obtained thereby
DE19627228A1 (de) 1996-07-05 1998-01-08 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
JP2004161664A (ja) 2002-11-13 2004-06-10 Fancl Corp プロポリス組成物
WO2004062563A2 (en) * 2003-01-16 2004-07-29 Université de Lausanne Methods for screening for therapeutic agents that are useful in the treatment of oxytocin and vasopressin-related disorders
GB0319119D0 (en) 2003-08-14 2003-09-17 Optinose As Delivery devices
JP2007526300A (ja) * 2004-03-04 2007-09-13 ジーイー・ヘルスケア・アクスイェ・セルスカプ 医薬化合物
MX2007003750A (es) 2004-09-29 2007-11-07 Ge Healthcare As Agentes de contraste enfocadores del receptor activador de plasminogeno de urocinasa (upar).
CA2689476C (en) 2007-06-07 2014-08-05 Nastech Pharmaceutical Company Inc. Intranasal carbetocin formulations and methods for the treatment of autism
JP2010085108A (ja) * 2008-09-29 2010-04-15 Nano Factory:Kk 生体光イメージング用プローブ
EP2416806B8 (en) * 2009-04-10 2017-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Fucoidans as ligands for the diagnosis of degenerative pathologies
JP2013521233A (ja) * 2010-02-25 2013-06-10 ヤンセン アルツハイマー イミュノセラピー Ａβを標的とする免疫療法のＰＥＴモニタリング
US20130130985A1 (en) 2010-04-01 2013-05-23 Paul Alewood Oxytocin peptide analogues
JP2013230986A (ja) * 2010-08-25 2013-11-14 Kyorin Pharmaceutical Co Ltd 新規ヒダントイン誘導体及びそれらを有効成分とする医薬
JO3400B1 (ar) 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
JP6445861B2 (ja) 2014-12-18 2018-12-26 国立大学法人金沢大学 オキシトシン検出のためのサンプルの前処理方法
SG11201705591PA (en) 2015-01-07 2017-08-30 Trigemina Inc Magnesium-containing oxytocin formulations and methods of use
WO2017096036A1 (en) 2015-12-02 2017-06-08 The Regents Of The University Of Michigan Her2 peptide regents and methods
EP3759121A1 (en) 2018-03-01 2021-01-06 Trigemina, Inc. Labeled oxytocin and method of manufacture and use

Similar Documents

Publication Publication Date Title
JP2021515005A5 (https=)
JP6356876B2 (ja) 抗ウイルス化合物の合成
CN104812384B (zh) 二取代的氨基酸及其制备和使用方法
JP3271259B2 (ja) 改良された放射性標識
Van Staveren et al. Conjugation of a novel histidine derivative to biomolecules and labelling with [99m Tc (OH 2) 3 (CO) 3]+
JP2021532784A5 (https=)
JP2006528644A5 (https=)
JP2010503618A5 (https=)
CN105848687B (zh) 放射性示踪剂组合物和方法
JP5750209B2 (ja) 機能性分子、機能性分子合成用アミダイド、及び標的物質解析方法
CN103889999A (zh) 用于合成寡核糖核苷酸的离子标记
KR20090085599A (ko) Ｐｅｔ 영상화용 규소 유도체
JPWO2019169342A5 (https=)
AU2016335061A1 (en) New methods for making barusiban and its intermediates
JP6067580B2 (ja) オキシム連結反応の放射性安定化におけるアニリンの使用
CA2662439A1 (en) Compounds as aptamer-dimers and their uses in diagnosis and therapy
AU2018298658B2 (en) Improved process for preparing imetelstat
EP1908472A1 (en) Silicon derivatives for PET imaging
EP2964661B1 (en) Metallocene compounds and labeled molecules comprising the same for in vivo imaging
Chapleur et al. Toward imaging glycotools by click coupling
US12344625B2 (en) Process for preparing rhenium chelated MAG3 oligonucleotides
US20210163541A1 (en) Method for Preparing PNA Oligomer
Kriek et al. Chemical synthesis of picornaviral protein primers of RNA replication
RU2795447C1 (ru) Способ получения конъюгата boc-thz-phe-d-trp-lys(boc)-thr-nhch2ch2nh-dota, являющегося прекурсором для противоопухолевых радиофармпрепаратов
JPWO2019178479A5 (https=)